FDA
-
-
-
-
-
-
-
Polyrizon completes FDA pre-submission meeting for PL-14 nasal spray
-
-
-
-
-
-
-
Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model
-
-
-
-
-
-
-
Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

